Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nimotuzumab

A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	Thera-CIM-hr3 TheraCim hR3
Foreign brand name:	Theraloc
Code name:	H-R3 hR3

nimotuzumab

Search NCI's Drug Dictionary